8-K: Marker Therapeutics Reports Year-End 2024 Results and Corporate Updates, Highlighting Progress in Lymphoma and Pancreatic Cancer Programs

Marker Therapeutics announced its year-end 2024 financial results and provided corporate updates, emphasizing the advancement of its MT-601 program and strategic financing initiatives.

Summary

• Marker Therapeutics reported its financial results for the year ended December 31, 2024, along with corporate updates.
• The company's lead program, MT-601, is being investigated in patients with refractory lymphomas, including those who relapsed after anti-CD19 CAR-T cell therapy.
• Preliminary data from the Phase 1 APOLLO study showed a 78% objective response rate in lymphoma patients, with 44.4% achieving complete responses.
• Marker Therapeutics secured over $13 million in non-dilutive funding from CPRIT and NIH to support pancreatic and lymphoma clinical programs.
• The company received approval for neldaleucel as the nonproprietary name for MT-601.
• A strategic financing was completed to support clinical advancements of MT-601 in lymphoma patients.
• At the end of 2024, Marker Therapeutics had $19.2 million in cash and cash equivalents.
• The company believes its existing cash will fund operations into the first quarter of 2026, with potential extension from additional grant funding.
• Research and development expenses were $13.5 million for the year ended December 31, 2024.
• General and administrative expenses were $4.2 million for the year ended December 31, 2024.
• Marker Therapeutics reported a net loss of $10.7 million for the year ended December 31, 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to encouraging clinical data, strategic financing, and non-dilutive funding. However, the net loss and inherent risks associated with clinical-stage companies temper the overall sentiment.

Positives

• The APOLLO study showed encouraging safety and efficacy results for MT-601 in lymphoma patients.
• The company strengthened its financial position through non-dilutive funding and a private placement.
• Clinical program launch is anticipated in the second half of 2025 for MT-601 in pancreatic cancer.
• The company anticipates clinical program initiation during the second half of 2025 for MT-401-OTS.

Negatives

• Marker Therapeutics reported a net loss of $10.7 million for the year ended December 31, 2024, compared to a net loss of $8.2 million for the year ended December 31, 2023.

Risks

• The company's future performance is subject to risks and uncertainties, including those related to research, development, and regulatory activities.
• The company's ability to extend its cash runway beyond Q1 2026 depends on receiving additional grant funds.

Future Outlook

Marker Therapeutics expects its existing cash and cash equivalents to fund operating expenses into the first quarter of 2026, with potential extension from additional grant funding. The company plans to report further data on the APOLLO trial and initiate clinical programs for MT-601 in pancreatic cancer and MT-401-OTS in AML/MDS during the second half of 2025.

Management Comments

• Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, stated that the company made substantial progress advancing MT-601 and laid the groundwork for continued momentum in 2025.
• Dr. Vera believes MT-601 has the potential to provide a transformative treatment option for lymphoma patients who relapsed after anti-CD19 CAR-T cell therapy.
• Dr. Vera concluded that the company's focus remains on cash preservation and disciplined execution to maximize the impact of its clinical programs.

Industry Context

Marker Therapeutics is operating in the competitive immuno-oncology space, focusing on T cell-based therapies. The company's MAR-T cell platform offers a novel approach compared to genetically modified CAR-T cell therapies, potentially providing advantages in safety, manufacturing, and efficacy.

Comparison to Industry Standards

• The 78% objective response rate observed in the APOLLO study for MT-601 in relapsed lymphoma patients is competitive with other CAR-T cell therapies targeting similar patient populations.
• Companies like Kite Pharma (Gilead) and Novartis have established CAR-T cell therapies for lymphoma, but MT-601's multi-antigen approach could offer a differentiated benefit in preventing tumor escape.
• The non-dilutive funding secured by Marker Therapeutics from CPRIT and NIH is a positive indicator of the potential of its programs and aligns with industry trends of government support for innovative cancer therapies.

Related Party Transactions

• Related party payable increased from $1,329,655 in 2023 to $1,710,500 in 2024.

Stakeholder Impact

• Shareholders may be positively impacted by the encouraging clinical data and strategic financing.
• Employees are likely to be impacted by the company's focus on cash preservation and disciplined execution.
• Patients with lymphoma and pancreatic cancer may benefit from the development of MT-601.
• The company's suppliers and partners may be impacted by its clinical program advancements.

Next Steps

• The company will continue enrolling study participants in the Phase 1 APOLLO trial.
• Marker Therapeutics expects to report further data on the Phase 1 APOLLO trial in the second half of 2025.
• The company anticipates clinical program launch for MT-601 in metastatic pancreatic cancer in the second half of 2025.
• Marker Therapeutics anticipates clinical program initiation for MT-401-OTS in AML/MDS during the second half of 2025.
• The company plans to share additional insights during a webinar in the second quarter of 2025.

Key Dates

Keywords

Marker Therapeutics, MT-601, Lymphoma, Pancreatic Cancer, Immunotherapy, MAR-T cells, Clinical Trial, Financial Results, Neldaleucel, APOLLO study